Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 22, 2026
DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS
04:50am, Sunday, 01'st Mar 2026
DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities
Exact Sciences Stockholders Approve Acquisition by Abbott
04:05pm, Friday, 20'th Feb 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders vot
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock
10:50am, Thursday, 19'th Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up
09:21am, Thursday, 19'th Feb 2026
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS
04:18am, Thursday, 19'th Feb 2026
Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Co
Paul Tudor Jones Makes Significant Moves with iShares Core S&P 500 ETF
06:11pm, Tuesday, 17'th Feb 2026
Exploring the Latest 13F Filing and Investment Strategies Paul Tudor Jones (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025
CSLLY vs. EXAS: Which Stock Is the Better Value Option?
12:40pm, Monday, 16'th Feb 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks off
George Soros Reduces Stake in Smurfit WestRock PLC by 68.99%
12:00pm, Monday, 16'th Feb 2026
Insight into Soros's Strategic Moves in Q4 2025 George Soros (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing in
Exact Sciences Corporation $EXAS Shares Sold by AlphaQuest LLC
03:23am, Monday, 16'th Feb 2026
AlphaQuest LLC cut its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 89.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exc
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
06:08pm, Sunday, 15'th Feb 2026
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
06:15pm, Friday, 13'th Feb 2026
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.
Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops
05:35pm, Friday, 13'th Feb 2026
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
04:05pm, Friday, 13'th Feb 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for
Alger Mid Cap 40 ETF Q4 2025 Portfolio Update
12:38pm, Thursday, 12'th Feb 2026
The Alger Mid Cap 40 ETF underperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Micron Technology, Inc. and MongoDB, Inc. were among the top cont
Baron Opportunity Fund Q4 2025 Portfolio Activity
01:20am, Thursday, 12'th Feb 2026
We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterpri
